MiNK Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
Disclosure in lieu of reporting on a Current Report on Form 8-K.
Departure of Principal Accounting Officer
On May 12, 2026, Austin Charette, Principal Accounting Officer of the Company, informed the Company he will be resigning effective May 29, 2026.
Insider trading arrangements and policies
Trading Plans of Our Directors and Officers
During the quarter ended March 31, 2026, none of our directors or executive officers adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each item is defined in Item 408 of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.